Last reviewed · How we verify
lithium and Venlafaxine
Lithium and Venlafaxine, marketed by the Icahn School of Medicine at Mount Sinai, is a combination therapy with a key composition patent expiring in 2028. The primary strength of this drug lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the potential loss of exclusivity post-2028, which could lead to increased competition and revenue erosion.
At a glance
| Generic name | lithium and Venlafaxine |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Treatment of Adolescent Suicide Attempters (TASA) (PHASE2, PHASE3)
- Predictors of the Outcome of Late Life Depression
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Prolonging Remission in Depressed Elderly (PRIDE) (PHASE4)
- Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lithium and Venlafaxine CI brief — competitive landscape report
- lithium and Venlafaxine updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI